Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates

Rhea-AI Summary

Lifeward (Nasdaq: LFWD) announced a distribution agreement with Singapore-based Verita Neuro to exclusively distribute the ReWalk Personal Exoskeleton initially in Mexico, Thailand, and the United Arab Emirates effective Dec. 17, 2025.

Verita will integrate ReWalk into intensive, daily in-patient neurorehabilitation programs and offer patient-specific setup and training, leveraging an international database of >25,000 spinal cord injury patients. Lifeward said the partnership supports a partner-led, capital-efficient commercial expansion and cites a $1.75 billion total addressable market for ReWalk.

News Market Reaction – LFWD

+0.09%

9 alerts

+0.09% News Effect

+6.0% Peak in 27 hr 31 min

+$12K Valuation Impact

$13M Market Cap

0.2x Rel. Volume

On the day this news was published, LFWD gained 0.09%, reflecting a mild positive market reaction. Argus tracked a peak move of +6.0% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $12K to the company's valuation, bringing the market cap to $13M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

SCI survivors globally: Over 7 million Total addressable market: $1.75 billion Patient database: Over 25,000 patients +1 more

4 metrics

SCI survivors globally Over 7 million Global spinal cord injury survivor population mentioned as potential user base

Total addressable market $1.75 billion Estimated TAM for Lifeward’s ReWalk exoskeleton

Patient database Over 25,000 patients Verita Neuro’s international spinal cord injury patient database

New distribution countries 3 countries Exclusive initial distribution in Mexico, Thailand, United Arab Emirates

Market Reality Check

Price: $0.4251 Vol: Volume 204,068 is below t...

low vol

$0.4251 Last Close

Volume Volume 204,068 is below the 20-day average of 865,546, indicating muted pre‑news trading interest. low

Technical Shares at 0.6398 are trading below the 200-day MA of 0.95, reflecting a longer-term downtrend.

Peers on Argus

Sector peers showed mixed moves: RSLS gained 29.8%, while PAVM, BMRA, and HSCS d...

Sector peers showed mixed moves: RSLS gained 29.8%, while PAVM, BMRA, and HSCS declined modestly. With LFWD up 2.94% and no peers in momentum scanners, today’s international distribution news appears more company-specific than part of a broad sector rotation.

Historical Context

5 past events · Latest: Dec 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 03	Reimbursement expansion	Positive	+25.4%	Humana Medicare Advantage prior authorization expanding ReWalk 7 coverage.
Nov 17	Reimbursement approval	Positive	-0.5%	UnitedHealthcare Medicare Advantage prior authorization for ReWalk 7 device.
Nov 14	Earnings release	Positive	+14.9%	Q3 2025 results with higher revenue, lower cash burn, reaffirmed guidance.
Nov 10	Earnings date notice	Neutral	+4.1%	Scheduled announcement and call for upcoming Q3 2025 financial results.
Sep 09	Payment milestone	Positive	+3.9%	First commercial Medicare Advantage payment for ReWalk 7 exoskeleton.

Pattern Detected

LFWD has generally reacted positively to reimbursement and operational updates, with one recent divergence on favorable payer news.

Recent Company History

Over the past few months, Lifeward has focused on reimbursement and operational scaling for its ReWalk exoskeleton. On Sep 9, 2025, it reported its first commercial Medicare Advantage payment, followed by a Q3 2025 report on Nov 14 with $6.2M revenue and reduced cash burn. UnitedHealthcare and then Humana Medicare Advantage prior authorizations in mid‑November and early December expanded U.S. access. Today’s announcement extends that trajectory by targeting new international markets via a partner-led model.

Market Pulse Summary

This announcement extends Lifeward’s commercial reach by granting Verita Neuro exclusive rights to d...

Analysis

This announcement extends Lifeward’s commercial reach by granting Verita Neuro exclusive rights to distribute the ReWalk Personal Exoskeleton in Mexico, Thailand, and the United Arab Emirates. The deal leverages Verita’s database of over 25,000 spinal cord injury patients and shifts delivery toward intensive in‑patient neurorehabilitation programs. In context of earlier reimbursement and scaling milestones, investors may watch how quickly this partner-led, capital-efficient model converts the estimated $1.75 billion market into realized sales.

Key Terms

spinal cord injury, neurorehabilitation, epidural stimulation, stem cell therapy, +2 more

6 terms

spinal cord injury medical

"Over 7 million survivors of spinal cord injury (SCI) globally could potentially benefit"

Damage to the bundle of nerves that runs down the middle of the back and carries messages between the brain and the body; like a cut or crush to an electrical cable that disrupts signals to limbs and organs. It matters to investors because the severity and permanence of the damage drive demand for medical devices, drugs, rehabilitation services and long-term care, shaping the commercial size, regulatory hurdles and revenue timelines for companies developing treatments.

neurorehabilitation medical

"an intensive, daily, in-patient neurorehabilitation program"

Neurorehabilitation is the set of therapies and technologies used to help people regain or improve movement, thinking, speech, and daily function after injury or disease of the brain, spinal cord, or nerves — like retraining damaged wiring in a house so appliances work again. It matters to investors because demand, regulatory approvals, reimbursement rules, and technological advances can drive revenue and market growth for medical device makers, therapy providers, and drug developers in a growing, long‑term care market.

epidural stimulation medical

"Verita Neuro redefined epidural stimulation reconnecting brain-body pathways"

Epidural stimulation is a medical technique that delivers mild electrical pulses to the surface of the spinal cord through a device implanted near the spine, aiming to restore or improve movement, sensation, or autonomic functions after injury or disease. For investors, it matters because it represents a growing category of implantable neurotechnology with potential clinical benefits, regulatory milestones, reimbursement pathways, and commercial opportunity, but also carries clinical trial, safety, and approval risks.

stem cell therapy medical

"Verita Neuro modalities include surgical neural stimulation, stem cell therapy, and neurorehabilitation"

Therapies that use special cells capable of becoming different tissue types to repair, replace, or support damaged organs and systems—think of them as tiny seeds planted to regrow or fix parts of the body. Investors care because successful stem cell therapies can create entirely new markets or transform treatment costs, but they also carry long development timelines, high research and regulatory risk, and uncertain commercial returns until proven safe and effective.

neural stimulation medical

"Verita Neuro modalities include surgical neural stimulation, stem cell therapy"

Neural stimulation is the use of devices or targeted techniques to send small electrical or other signals to nerves or brain areas to change how they function, similar to turning a dial or nudging a circuit to alter output. Investors care because these therapies can offer new treatment options for conditions that drugs struggle to treat, creating commercial opportunity but also depending heavily on clinical proof, regulatory approval, safety and reimbursement decisions.

autonomic functions medical

"to regain voluntary movement and vital autonomic functions"

Autonomic functions are the body’s automatic processes—like heart rate, breathing, blood pressure, digestion and temperature control—run by the involuntary nervous system so you don’t have to think about them. For investors, these functions matter because drugs, devices or procedures that change them can be key measures of safety and effectiveness, affect regulatory approval and shape market potential; think of them as the body’s autopilot whose behavior determines product risks and benefits.

AI-generated analysis. Not financial advice.

Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities

New delivery model for ReWalk will integrate in-patient training and rehabilitation to support clinical adoption in physical rehabilitation settings

Over 7 million survivors of spinal cord injury (SCI) globally could potentially benefit from ReWalk, an estimated $1.75 billion total addressable market for Lifeward

MARLBOROUGH, Mass., YOKNEAM ILLIT, Israel and BERLIN, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today the expansion of patient access to the ReWalk Personal Exoskeleton through a new international distribution agreement with Verita Neuro, a Verita Healthcare Ltd. company. This collaboration supports Lifeward’s long-term growth strategy by extending its commercial footprint into new international markets through a partner-led, capital-efficient model. Verita Neuro has an established international footprint, with the partnership launching across multiple international geographies. Verita Neuro will be the exclusive distributor of ReWalk initially in Mexico, Thailand, and the United Arab Emirates, where it has advanced centers that offer innovative treatments for people living with neurological and spinal cord injuries.

Verita Neuro offers unparalleled reach through its international database of over 25,000 spinal cord injury patients plus a growing network of international rehabilitation centers able to deliver highly personalized care.

“This latest distribution agreement with Verita Neuro is consistent with Lifeward’s strategy to expand global access to the ReWalk Personal Exoskeleton for patients with spinal cord injury, building our established distribution and reimbursement presence in the United States and Germany,” said Mark Grant, CEO of Lifeward. “The Company’s hybrid commercial model, combining direct sales in the United States with third-party distribution and servicing in select international markets, is intended to support increased sales volumes while managing operating expenses and advancing long-term, sustainable growth.”

Lifeward selected Verita as its partner in these targeted regions to integrate ReWalk into their multi-modal treatment methodologies for people living with neurological and spinal cord injuries. Today, Verita Neuro modalities include surgical neural stimulation, stem cell therapy, and neurorehabilitation.

Verita’s CEO, Julian Andriesz, commented, “As the global pioneer in neurological restoration, Verita Neuro redefined epidural stimulation reconnecting brain-body pathways to regain voluntary movement and vital autonomic functions. We are excited to empower our patients with the most cutting-edge robotic physical rehabilitation systems. Through Lifeward’s ReWalk exoskeleton in our in-patient program, we’re achieving another world first, seamless multimodal enablement.”

Verita will be performing patient-specific setup and training in the ReWalk Personal Exoskeleton in an intensive, daily, in-patient neurorehabilitation program. This new delivery method is an alternative to the current protocol of outpatient training and rehabilitation. We expect this progressive intensive in-patient program will support clinical adoption in physical rehabilitation settings across a range of patient cases and global markets.

About Verita

Verita Healthcare is a next generation integrated healthcare group offering precision diagnostics, leading-edge treatments and advanced Med-Tech solutions. Its healthcare ecosystem has expanded from the Asia Pacific Region to Europe, USA, South America and the Middle East. Wholly owned subsidiary, Verita Neuro, launched in 2015 is a global pioneer in advanced treatments for spinal cord injuries, brain injuries, stroke and other neurological conditions. As the first provider worldwide to offer epidural stimulation outside clinical trials, Verita Neuro combines neuromodulation, regenerative therapies and intensive rehabilitation to deliver personalized, life-changing care to patients from over 50 countries.

About Lifeward

Lifeward designs, develops, and commercializes life-changing solutions spanning the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings, as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products, including the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System. Founded in 2001, Lifeward has operations in the United States, Israel, and Germany.

Lifeward^®, ReWalk^®, ReStore^®, and Alter G^® are registered trademarks of Lifeward Ltd. and/or its affiliates.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward looking statements include, among others: the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; the impact of the distribution agreement on Lifeward’s revenue and cash flow; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2024 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Lifeward Media Relations:
Almog Adar
Chief Financial Officer
E: media@golifeward.com

Lifeward Investor Contact:
Almog Adar
Chief Financial Officer
Lifeward
E: ir@golifeward.com

FAQ

What markets will Lifeward (LFWD) expand ReWalk distribution into with Verita Neuro on Dec. 17, 2025?

Lifeward named Mexico, Thailand, and the United Arab Emirates as the initial exclusive ReWalk distribution territories under the agreement.

How will Verita Neuro deliver ReWalk services for LFWD patients in the new markets?

Verita will provide intensive, daily in-patient neurorehabilitation with patient-specific setup and training for the ReWalk Personal Exoskeleton.

What patient reach did Lifeward cite for Verita Neuro in the LFWD distribution agreement?

The company said Verita Neuro has an international database of over 25,000 spinal cord injury patients and a growing network of rehabilitation centers.

Does the Lifeward (LFWD) announcement disclose financial terms or contract value for the Verita agreement?

No; the announcement describes the exclusive distribution and delivery model but does not disclose any financial terms or contract value.

What market size did Lifeward cite for the ReWalk Personal Exoskeleton in the Dec. 17, 2025 release?

Lifeward estimated a $1.75 billion total addressable market and referenced >7 million global spinal cord injury survivors who could potentially benefit.